Aurinia Pharma and partner Otsuka have secured approval in the EU for Lupkynis, billed as the first oral treatment for active nephritis in patients with the autoimmune disease systemic lupus ...

When discomfort surrounding these issues is compounded by a diagnosis of systemic lupus erythematosus (SLE or commonly called lupus), challenges to a satisfying sex life and open communication may be ...

1. What is the risk of cardiovascular disease in lupus? Cardiovascular Disease (CVD) commonly refers to issues involved in coronary heart disease, including heart attacks, cerebrovascular disease, or ...

May 14, 2025 — Some patients with lupus who possess specific antibodies are at a higher risk of thrombotic events such as a blood clot, stroke or heart attack, a new study shows. The finding ...

Objectives While diffuse alveolar haemorrhage (DAH) is recognised as a life-threatening complication of systemic lupus erythematosus (SLE), little is known about its risk factors and response to ...

The mechanisms governing immune-related adverse events resulting from checkpoint inhibition therapy for cancer remain a mystery to rheumatologists and oncologists alike, according to a presenter ...

Severe neurological involvement in systemic lupus erythematosus (NPSLE) is one of the most dreadful complications of the disease. Objective: To identify the best drug, dose, and treatment. Patients ...